Brixadi (buprenorphine) extended-release subcutaneous injection treats moderate to severe opioid use disorder (OUD) in patients who have started treatment with a single dose of a transmucosal buprenorphine product (like Suboxone) or who are already being treated with buprenorphine.
Brixadi comes in weekly or monthly formulations for subcutaneous injection into the buttock, thigh, abdomen or upper arm. It helps break the cycle of cravings and withdrawal as a key part of a comprehensive treatment program.